Turing Pharmaceuticals CEO Martin Shkreli
Turing Pharmaceuticals CEO Martin Shkreli gained worldwide notoriety after it was revealed that his company increased the cost of Daraprim by
4,000% overnight, shortly after buying the rights to the drug. After worldwide outrage, Shkreli eventually caved and announced Turing Pharmaceuticals
would lower the price after all.
Today Lindsey Ramsey at the Tech Insider reports that the high cost still hasn't been lowered:
In September, he told ABC News, “We’ve agreed to lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit."
That hasn't happened yet. A 30-day, 30-pill supply of Daraprim would cost me $27,006 at my local pharmacy.
That boils down to about $900 a pill, which includes the wholesale cost, along with specific pharmacy fees based on the zip code I gave the pharmacy.
So while the price of the drug hasn't gotten any higher since Shkreli hiked it 5,000%, it hasn't gotten any lower since he promised to reduce it either. Turing did not respond to Business Insider's request for clarification about this price.
Meanwhile, Shkreli is still defending the hike on
his Twitter account, along with numerous disparaging tweets about Hillary Clinton because she publicly stated her opposition to price-gouging.